WO2022258060A1 - Forme cristalline de lanifibranor et son procédé de préparation - Google Patents

Forme cristalline de lanifibranor et son procédé de préparation Download PDF

Info

Publication number
WO2022258060A1
WO2022258060A1 PCT/CN2022/098241 CN2022098241W WO2022258060A1 WO 2022258060 A1 WO2022258060 A1 WO 2022258060A1 CN 2022098241 W CN2022098241 W CN 2022098241W WO 2022258060 A1 WO2022258060 A1 WO 2022258060A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal form
lanifibranor
crystal
solvent
crystalline form
Prior art date
Application number
PCT/CN2022/098241
Other languages
English (en)
Chinese (zh)
Inventor
刘天杰
高沛琳
申淑匣
张良
Original Assignee
上海启晟合研医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海启晟合研医药科技有限公司 filed Critical 上海启晟合研医药科技有限公司
Priority to CN202280036190.5A priority Critical patent/CN117545755A/zh
Publication of WO2022258060A1 publication Critical patent/WO2022258060A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the invention relates to the field of medicinal chemistry, in particular to a crystal form of Lanifibranor and a preparation method thereof.
  • Nonalcoholic steatohepatitis is an extreme form of nonalcoholic fatty liver disease, defined as steatosis accompanied by inflammation and hepatocellular damage. NASH can lead to advanced liver fibrosis, cirrhosis, liver failure and the development of liver tumors.
  • Lanifibranor is a pan-PPAR agonist, which produces a balanced activation of PPAR ⁇ and PPAR ⁇ , and can partially activate PPAR ⁇ . Under the action of multiple mechanisms, Lanifibranor has shown good efficacy in clinical studies of nonalcoholic steatohepatitis and security.
  • the chemical name of the drug is: 5-chloro-1-[(6-benzothiazolyl)sulfonyl]-1H-indole-2-butyric acid, the molecular formula is: C 19 H 15 ClN 2 O 4 S 2 , the molecular weight It is: 434.92, the CAS number is: 927961-18-0, and the chemical structural formula is as shown in formula (I):
  • the polymorphic form of drugs is a crucial research content.
  • Different crystal forms have different solubility, dissolution rate, and stability, which will significantly affect the bioavailability of the drug, which in turn will lead to different clinical effects.
  • the impact of crystal form is greater.
  • WO2007026097A1 discloses Lanifibranor compounds and their preparation methods.
  • Example 117 of this patent discloses that a light yellow powder is obtained, but its melting point is low, only 74-80°C, and its stability may be poor in terms of melting point.
  • the inventors of the present application unexpectedly discovered that the compound I crystal forms CM-A, CM-B, CM-C, CM-D, CM-E, CM-F, CM- G and CM-I. It has advantages in at least one aspect of melting point, stability, solubility, hygroscopicity, dissolution in vivo and in vitro, bioavailability, compressibility, fluidity, preparation quality and processing performance, especially melting point, stability, Wettability, fluidity, preparation tablet uniformity and preparation process operability provide a new and better choice for the development of drugs containing Lanifibranor, which is of great significance.
  • CM-A, CM-B, CM-F and CM-I have better solubility and fluidity than the prior art, which is of great significance to the dissolution of subsequent preparations; they have little electrostatic effect , the advantages of being suitable for the production of preparations; the preparation process is simple, the operability is strong, the yield is high, the quality is stable, the production cycle is short, and it is easy to realize large-scale production.
  • the purpose of the present invention is to provide a new crystal form of Lanifibranor with high melting point and good stability, so as to meet the needs of drug development and application.
  • Another object of the present invention is to provide a method for preparing a new crystal form of Lanifibranor suitable for formulation production.
  • the first aspect of the present invention provides a crystal form of the compound represented by formula I, characterized in that,
  • the crystal form is selected from the group consisting of crystal form CM-A, crystal form CM-B, crystal form CM-C, crystal form CM-D, crystal form CM-E, crystal form CM-F, and crystal form CM-G or crystalline form CM-I.
  • the crystalline form is crystalline form CM-A.
  • the XRPD pattern of the crystalline form CM-A includes 2 or more 2 ⁇ values selected from the following group: 9.9° ⁇ 0.2°, 15.65° ⁇ 0.2°, 23.95° ⁇ 0.2°. More preferably, the XRPD pattern of the crystalline form CM-A also includes one or more 2 ⁇ values selected from the following group: 11.70° ⁇ 0.2°, 17.26° ⁇ 0.2°, 20.10° ⁇ 0.2°, 20.57° ⁇ 0.2°.
  • the diffraction angle 2 ⁇ value of the XRPD pattern of the crystal form CM-A is 9.90° ⁇ 0.2°, 11.70° ⁇ 0.2°, 12.62° ⁇ 0.2°, 14.99° ⁇ 0.2°, 15.65° ⁇ 0.2 °, 17.26° ⁇ 0.2°, 17.96° ⁇ 0.2°, 18.49° ⁇ 0.2°, 20.10° ⁇ 0.2°, 20.57° ⁇ 0.2°, 21.48° ⁇ 0.2°, 22.20° ⁇ 0.2°, 22.60° ⁇ 0.2°, 23.41° ⁇ 0.2°, 23.95° ⁇ 0.2°, 25.02° ⁇ 0.2°, 26.05° ⁇ 0.2°, 26.71° ⁇ 0.2°, 27.00° ⁇ 0.2°, 27.32° ⁇ 0.2°, 29.04° ⁇ 0.2°, 30.01° There are characteristic peaks at ⁇ 0.2°, 30.43° ⁇ 0.2° and 31.78° ⁇ 0.2°.
  • the crystal form CM-A has no obvious weight loss peak at 25°C-200°C.
  • the crystal form CM-A has an endothermic peak at 114.80°C and 179.34°C respectively.
  • the crystalline form CM-A has XRPD data substantially as shown in Table A.
  • the crystalline form CM-A has an XRPD spectrum substantially as shown in FIG. 1 .
  • the crystalline form CM-A has a TGA spectrum substantially as shown in FIG. 2 .
  • the crystalline form CM-A has a DSC spectrum substantially as shown in FIG. 3 .
  • the crystalline form CM-A has a 1H NMR spectrum substantially as shown in FIG. 4 .
  • the crystal form CM-A is block or cuboid crystal.
  • the crystal form is crystal form CM-B.
  • the XRPD pattern of the crystalline form CM-B includes 2 or more 2 ⁇ values selected from the following group: 7.75° ⁇ 0.2°, 10.89° ⁇ 0.2°, 20.18° ⁇ 0.2°, 22.18 ° ⁇ 0.2°. More preferably, the XRPD pattern of the crystalline form CM-B also includes one or more 2 ⁇ values selected from the following group: 8.36° ⁇ 0.2°, 16.41° ⁇ 0.2°, 16.98° ⁇ 0.2°, 17.83° ⁇ 0.2°, 19.14° ⁇ 0.2°.
  • the diffraction angle 2 ⁇ value of the XRPD pattern of the crystal form CM-B is 7.75° ⁇ 0.2°, 8.36° ⁇ 0.2°, 10.89° ⁇ 0.2°, 13.99° ⁇ 0.2°, 15.60° ⁇ 0.2 °, 16.41° ⁇ 0.2°, 16.77° ⁇ 0.2°, 16.98° ⁇ 0.2°, 17.83° ⁇ 0.2°, 19.14° ⁇ 0.2°, 20.18° ⁇ 0.2°, 21.15° ⁇ 0.2°, 22.18° ⁇ 0.2°, 22.50° ⁇ 0.2°, 23.30° ⁇ 0.2°, 24.02° ⁇ 0.2°, 24.06° ⁇ 0.2°, 24.47° ⁇ 0.2°, 25.25° ⁇ 0.2°, 25.55° ⁇ 0.2°, 26.32° ⁇ 0.2°, 26.68° There are characteristic peaks at ⁇ 0.2°, 27.45° ⁇ 0.2°, 27.63° ⁇ 0.2°, 29.69° ⁇ 0.2°, 32.27° ⁇ 0.2° and 33.03° ⁇ 0.2°.
  • the crystal form CM-B has no obvious weight loss step at 25°C-150°C.
  • the crystal form CM-B has a melting endothermic peak at 178.97°C.
  • the crystal form CM-B has XRPD data substantially as shown in Table B.
  • the crystal form CM-B has an XRPD spectrum substantially as shown in FIG. 5 .
  • the crystal form CM-B has a TGA spectrum substantially as shown in FIG. 6 .
  • the crystalline form CM-B has a DSC spectrum substantially as shown in FIG. 7 .
  • the crystalline form CM-B has a 1H NMR spectrum substantially as shown in FIG. 8 .
  • the crystal form CM-B is a fine needle crystal.
  • the crystalline form is crystalline form CM-F.
  • the XRPD pattern of the crystalline form CM-F includes 2 or more 2 ⁇ values selected from the following group: 16.75° ⁇ 0.2°, 17.87° ⁇ 0.2°, 25.25° ⁇ 0.2°; more Preferably, the XRPD pattern of the crystalline form CM-F also includes one or more 2 ⁇ values selected from the following group: 19.16° ⁇ 0.2°, 20.14° ⁇ 0.2°, 21.11° ⁇ 0.2°, 22.20° ⁇ 0.2°, 24.09° ⁇ 0.2°, 24.40° ⁇ 0.2°.
  • the diffraction angle 2 ⁇ value of the XRPD pattern of the crystal form CM-F is 7.76° ⁇ 0.2°, 8.38° ⁇ 0.2°, 10.92° ⁇ 0.2°, 14.05° ⁇ 0.2°, 15.69° ⁇ 0.2 °, 16.48° ⁇ 0.2°, 16.75° ⁇ 0.2°, 17.01° ⁇ 0.2°, 17.87° ⁇ 0.2°, 19.16° ⁇ 0.2°, 20.14° ⁇ 0.2°, 21.11° ⁇ 0.2°, 22.20° ⁇ 0.2°, 22.56° ⁇ 0.2°, 23.30° ⁇ 0.2°, 24.09° ⁇ 0.2°, 24.40° ⁇ 0.2°, 25.25° ⁇ 0.2°, 25.58° ⁇ 0.2°, 26.35° ⁇ 0.2°, 27.57° ⁇ 0.2°, 28.16° There are characteristic peaks at ⁇ 0.2°, 29.60° ⁇ 0.2°, 32.25° ⁇ 0.2° and 33.92° ⁇ 0.2°.
  • the crystalline form CM-F has an endothermic peak at 178.50°C.
  • the crystal form CM-F has no obvious weight loss step in the range of 25°C-200°C.
  • the crystalline form CM-F has XRPD data substantially as shown in Table F.
  • the crystalline form CM-F has an XRPD spectrum substantially as shown in FIG. 20 .
  • the crystalline form CM-F has a TGA spectrum substantially as shown in FIG. 21 .
  • the crystalline form CM-F has a DSC spectrum substantially as shown in FIG. 22 .
  • the crystalline form CM-F has a 1H NMR spectrum substantially as shown in Figure 23.
  • the crystal form CM-F is a bulk crystal.
  • the crystalline form is crystalline form CM-I.
  • the XRPD pattern of the crystalline form CM-I includes 2 or more 2 ⁇ values selected from the following group: 7.83° ⁇ 0.2°, 9.70° ⁇ 0.2°, 18.43° ⁇ 0.2°; more
  • the XRPD pattern of the crystalline form CM-I also includes one or more 2 ⁇ values selected from the following group: 13.13° ⁇ 0.2°, 20.59° ⁇ 0.2°, 22.38° ⁇ 0.2°, 23.11° ⁇ 0.2°.
  • the diffraction angle 2 ⁇ value of the XRPD pattern of the crystal form CM-I is 2.50° ⁇ 0.2°, 7.83° ⁇ 0.2°, 9.70° ⁇ 0.2°, 13.13° ⁇ 0.2°, 15.76° ⁇ 0.2 °, 18.43° ⁇ 0.2°, 20.59° ⁇ 0.2°, 22.38° ⁇ 0.2°, 23.11° ⁇ 0.2°, 24.13° ⁇ 0.2°, 25.32° ⁇ 0.2°, 26.30° ⁇ 0.2°, 29.62° ⁇ 0.2° and There is a characteristic peak at 31.24° ⁇ 0.2°.
  • the crystalline form CM-I has an endothermic peak at 138.07°C and 176.11°C respectively.
  • the crystal form CM-I has obvious weight loss steps in the range of 100°C-175°C.
  • the crystalline form CM-I has XRPD data substantially as shown in Table H.
  • the crystalline form CM-I has an XRPD spectrum substantially as shown in FIG. 27 .
  • the crystalline form CM-I has a TGA spectrum substantially as shown in FIG. 28 .
  • the crystalline form CM-I has a DSC spectrum substantially as shown in FIG. 29 .
  • the crystalline form CM-I has a 1H NMR spectrum substantially as shown in Figure 30.
  • the crystal form CM-I is a short rod crystal.
  • the crystalline form is crystalline form CM-C.
  • the XRPD pattern of the crystalline form CM-C includes 2 or more 2 ⁇ values selected from the following group: 9.38° ⁇ 0.2°, 10.20° ⁇ 0.2°, 24.42° ⁇ 0.2°; more Preferably, the XRPD pattern of the crystalline form CM-C also includes one or more 2 ⁇ values selected from the following group: 16.36° ⁇ 0.2°, 17.78° ⁇ 0.2°, 19.06° ⁇ 0.2°, 22.16° ⁇ 0.2°, 23.44° ⁇ 0.2°, 27.54° ⁇ 0.2°.
  • the diffraction angle 2 ⁇ value of the XRPD pattern of the crystal form CM-C is 9.38° ⁇ 0.2°, 10.20° ⁇ 0.2°, 16.36° ⁇ 0.2°, 17.78° ⁇ 0.2°, 19.06° ⁇ 0.2 °, 22.16° ⁇ 0.2°, 23.44° ⁇ 0.2°, 24.42° ⁇ 0.2° and 27.54° ⁇ 0.2° have characteristic peaks.
  • the crystalline form CM-C has an obvious weight loss step at 100°C-200°C.
  • the crystalline form CM-C has a melting endothermic peak at 177.40°C.
  • the crystal form CM-C has XRPD data substantially as shown in Table C.
  • the crystalline form CM-C has an XRPD spectrum substantially as shown in FIG. 9 .
  • the crystalline form CM-C has a TGA spectrum substantially as shown in FIG. 10 .
  • the crystalline form CM-C has a DSC spectrum substantially as shown in FIG. 11 .
  • the crystalline form CM-C has a 1H NMR spectrum substantially as shown in FIG. 12 .
  • the crystalline form is crystalline form CM-D.
  • the XRPD pattern of the crystalline form CM-D includes 2 or more 2 ⁇ values selected from the following group: 5.74° ⁇ 0.2°, 9.15° ⁇ 0.2°, 16.39° ⁇ 0.2°; more Preferably, the XRPD pattern of the crystalline form CM-D also includes one or more 2 ⁇ values selected from the following group: 11.54° ⁇ 0.2°, 14.70° ⁇ 0.2°, 18.27° ⁇ 0.2°, 20.55° ⁇ 0.2°, 23.67° ⁇ 0.2°.
  • the diffraction angle 2 ⁇ value of the XRPD pattern of the crystal form CM-D is 5.74° ⁇ 0.2°, 9.15° ⁇ 0.2°, 11.54° ⁇ 0.2°, 14.70° ⁇ 0.2°, 16.39° ⁇ 0.2 °, 18.27° ⁇ 0.2°, 20.55° ⁇ 0.2° and 23.67° ⁇ 0.2° have characteristic peaks.
  • the crystalline form CM-D has an endothermic peak at 53.27°C, 101.22°C, 122.63°C and 171.01°C.
  • the crystalline form CM-D has a weight loss of about 10.08% in the range of room temperature-75°C, a weight loss of about 2.20% in the range of 75°C-115°C, a weight loss of about 5.08% in the range of 115°C-165°C, The weight loss is about 1.24% in the range of 165°C-210°C.
  • the crystal form CM-D has XRPD data substantially as shown in Table D.
  • the crystalline form CM-D has an XRPD spectrum substantially as shown in FIG. 13 .
  • the crystalline form CM-D has a TGA spectrum substantially as shown in FIG. 14 .
  • the crystalline form CM-D has a DSC spectrum substantially as shown in FIG. 15 .
  • the crystal form is crystal form CM-E.
  • the XRPD pattern of the crystalline form CM-E includes 2 or more 2 ⁇ values selected from the following group: 11.50° ⁇ 0.2°, 17.33° ⁇ 0.2°, 18.63° ⁇ 0.2°; more Preferably, the XRPD pattern of the crystalline form CM-E also includes one or more 2 ⁇ values selected from the following group: 6.97° ⁇ 0.2°, 9.14° ⁇ 0.2°, 13.02° ⁇ 0.2°, 13.83° ⁇ 0.2°, 19.52° ⁇ 0.2°, 21.54° ⁇ 0.2°.
  • the diffraction angle 2 ⁇ value of the XRPD pattern of the crystal form CM-E is 6.97° ⁇ 0.2°, 9.14° ⁇ 0.2°, 11.50° ⁇ 0.2°, 13.02° ⁇ 0.2°, 13.83° ⁇ 0.2 °, 17.33° ⁇ 0.2°, 18.63° ⁇ 0.2°, 19.52° ⁇ 0.2°, 21.54° ⁇ 0.2°, 22.57° ⁇ 0.2°, 23.15° ⁇ 0.2°, 23.63° ⁇ 0.2°, 24.51° ⁇ 0.2°, There are characteristic peaks at 24.57° ⁇ 0.2°, 25.46° ⁇ 0.2°, 27.65° ⁇ 0.2°, 28.92° ⁇ 0.2°, 29.78° ⁇ 0.2° and 32.32° ⁇ 0.2°.
  • the crystal form CM-E has an endothermic peak at 51.07°C, 95.75°C and 166.19°C, and an exothermic crystallization peak at 125.4°C.
  • the crystalline form CM-E has a weight loss of about 11.13% in the range of room temperature-78°C, a weight loss of about 3.30% in the range of 78°C-125°C, and a weight loss of about 1.05% in the range of 125°C-210°C.
  • the crystalline form CM-E has XRPD data substantially as shown in Table E.
  • the crystalline form CM-E has an XRPD spectrum substantially as shown in FIG. 16 .
  • the crystalline form CM-E has a TGA spectrum substantially as shown in FIG. 17 .
  • the crystalline form CM-E has a DSC spectrum substantially as shown in FIG. 18 .
  • the crystalline form CM-E has a 1H NMR spectrum substantially as shown in Figure 19.
  • the crystalline form is crystalline form CM-G.
  • the XRPD pattern of the crystalline form CM-G includes 2 or more 2 ⁇ values selected from the following group: 17.95° ⁇ 0.2°, 18.42° ⁇ 0.2°, 20.96° ⁇ 0.2°; more Preferably, the XRPD pattern of the crystalline form CM-G includes a 2 ⁇ value of 1 or more selected from the following group: 6.09° ⁇ 0.2°, 8.16° ⁇ 0.2°, 9.27° ⁇ 0.2°, 9.82° ⁇ 0.2°, 15.72° ⁇ 0.2°, 19.72° ⁇ 0.2°.
  • the diffraction angle 2 ⁇ value of the XRPD pattern of the crystal form CM-G is 6.09° ⁇ 0.2°, 8.16° ⁇ 0.2°, 9.27° ⁇ 0.2°, 9.82° ⁇ 0.2°, 15.72° ⁇ 0.2 °, 17.95° ⁇ 0.2°, 18.42° ⁇ 0.2°, 19.72° ⁇ 0.2°, 20.96° ⁇ 0.2°, 21.21° ⁇ 0.2°, 21.76° ⁇ 0.2°, 27.91° ⁇ 0.2°, 28.26° ⁇ 0.2°, There are characteristic peaks at 29.40° ⁇ 0.2°, 30.13° ⁇ 0.2°, 31.85° ⁇ 0.2° and 32.72° ⁇ 0.2°.
  • the crystalline form CM-G has a desolvation peak at 54.94°C, a melting transformation peak at 92.04°C, and an endothermic melting peak at 176.39°C.
  • the crystalline form CM-G loses about 20.56% in weight in the range of 17°C-88°C, and loses about 2.75% in the range of 88°C-158°C.
  • the crystalline form CM-G has XRPD data substantially as shown in Table G.
  • the crystalline form CM-G has an XRPD spectrum substantially as shown in FIG. 24 .
  • the crystalline form CM-G has a TGA spectrum substantially as shown in FIG. 25 .
  • the crystalline form CM-G has a DSC spectrum substantially as shown in FIG. 26 .
  • the second aspect of the present invention provides a method for preparing the crystal form described in the first aspect of the present invention.
  • the crystal form is crystal form CM-A, and its preparation method includes the following steps:
  • the first solvent is selected from the group consisting of ketone solvents, alcohol solvents, ester solvents, or combinations thereof. More preferably, the ketone solvent is acetone and/or 2-butanone; the alcohol solvent is methanol and/or ethanol; and the ester solvent is ethyl acetate.
  • the first solvent is 2-methyltetrahydrofuran.
  • step (1) is carried out at room temperature.
  • the mass (g)/volume (mL) of the Lanifibranor raw material and the first solvent is 1:10-100, preferably 1:10-50, more preferably 1 :10 ⁇ 20.
  • the crystal form is crystal form CM-B, and its preparation method includes the following steps:
  • Lanifibranor raw material is provided in a second solvent to form a mixture or solution containing Lanifibranor raw material;
  • the second solvent is an ether solvent and/or an ester solvent. More preferably, the ether solvent is methyl tert-butyl ether and/or anisole; the ester is ethyl acetate.
  • step (1) is carried out at room temperature.
  • the mass (g)/volume (mL) of the Lanifibranor raw material and the second solvent is 1:10-50, preferably 1:20-40.
  • the crystal form is crystal form CM-F, and its preparation method includes the following steps:
  • the third solvent is selected from the group consisting of dimethyl sulfoxide (DMSO), N-N dimethylacetamide, N-methylpyrrolidone (NMP), or combinations thereof.
  • DMSO dimethyl sulfoxide
  • NMP N-methylpyrrolidone
  • the third solvent is N-N dimethylacetamide.
  • the third solvent is dimethyl sulfoxide.
  • step (1) is carried out at room temperature.
  • the mass (g)/volume (mL) of the Lanifibranor raw material and the third solvent is 1:10-100, preferably 1:10-50, more preferably 1:10-20.
  • the medium is a glass vial.
  • the crystal form is crystal form CM-I, and its preparation method includes the following steps:
  • the fourth solvent is alcohol solvent and/or dichloromethane. More preferably, the alcoholic solvent is methanol and/or ethanol.
  • the weight volume ratio of the Lanifibranor raw material to the fourth solvent is 1:10-100, preferably 1:10-50, more preferably 1:10-20.
  • the high polymer is polyvinyl alcohol and/or polyvinyl chloride.
  • the seed crystal is crystal form CM-A and/or CM-I.
  • the added seed crystal or high polymer is 0.3-10 wt%, preferably 0.5-5 wt%, of the mass of the Lanifibranor raw material.
  • step (1) is carried out at room temperature.
  • the volatilization temperature of the solution is 20-80°C.
  • the volatilization time is 1-48h; preferably 2-36h; more preferably 3-24h.
  • an optional drying step is also included.
  • the method of collecting solids is filtering.
  • the third aspect of the present invention provides a pharmaceutical composition
  • the pharmaceutical composition contains (a) active ingredient, the active ingredient is the Lanifibranor crystal form as described in the first aspect of the present invention; and (b) pharmaceutical acceptable carrier.
  • the dosage form of the pharmaceutical composition or preparation is selected from the group consisting of powder injection, capsule, granule, tablet, pill or injection.
  • the fourth aspect of the present invention provides a use of the crystal form as described in the first aspect of the present invention, the use comprising: 1) preparing a compound of formula (I) or a salt thereof; 2) preparing a compound for the treatment of non-alcoholic Drugs for steatohepatitis.
  • Figure 1 is the XRPD spectrum of the crystalline form CM-A of Lanifibranor according to the present invention.
  • Fig. 2 is the TGA spectrum of the crystalline form CM-A of Lanifibranor according to the present invention.
  • Fig. 3 is the DSC spectrum of the crystalline form CM-A of Lanifibranor according to the present invention.
  • Fig. 4 is the 1H NMR spectrogram of the crystalline form CM-A of Lanifibranor according to the present invention.
  • Fig. 5 is the XRPD spectrum of the crystalline form CM-B of Lanifibranor according to the present invention.
  • Fig. 6 is a TGA spectrum of the crystalline form CM-B of Lanifibranor according to the present invention.
  • Fig. 7 is the DSC spectrum of the crystalline form CM-B of Lanifibranor according to the present invention.
  • Fig. 8 is the 1H NMR spectrum of the crystalline form CM-B of Lanifibranor according to the present invention.
  • Fig. 9 is the XRPD spectrum of the crystalline form CM-C of Lanifibranor according to the present invention.
  • Fig. 10 is the TGA spectrum of the crystalline form CM-C of Lanifibranor according to the present invention.
  • Fig. 11 is the DSC spectrum of the crystalline form CM-C of Lanifibranor according to the present invention.
  • Fig. 12 is the 1H NMR spectrum of the crystalline form CM-C of Lanifibranor according to the present invention.
  • Fig. 13 is the XRPD spectrum of the crystalline form CM-D of Lanifibranor according to the present invention.
  • Fig. 14 is the TGA spectrum of the crystalline form CM-D of Lanifibranor according to the present invention.
  • Fig. 15 is a DSC spectrum of the crystalline form CM-D of Lanifibranor according to the present invention.
  • Figure 16 is the XRPD spectrum of the crystalline form CM-E of Lanifibranor according to the present invention.
  • Fig. 17 is a TGA spectrum of the crystalline form CM-E of Lanifibranor according to the present invention.
  • Figure 18 is the DSC spectrum of the crystalline form CM-E of Lanifibranor according to the present invention.
  • Figure 19 is the 1H NMR spectrum of the crystalline form CM-E of Lanifibranor according to the present invention.
  • Figure 20 is the XRPD spectrum of the crystalline form CM-F of Lanifibranor according to the present invention.
  • Fig. 21 is the TGA spectrum of the crystalline form CM-F of Lanifibranor according to the present invention.
  • Figure 22 is the DSC spectrum of the crystalline form CM-F of Lanifibranor according to the present invention.
  • Figure 23 is the 1H NMR spectrum of the crystalline form CM-F of Lanifibranor according to the present invention.
  • Figure 24 is the XRPD spectrum of the crystalline form CM-G of Lanifibranor according to the present invention.
  • Fig. 25 is the TGA spectrum of the crystalline form CM-G of Lanifibranor according to the present invention.
  • Fig. 26 is a DSC spectrum of the crystalline form CM-G of Lanifibranor according to the present invention.
  • Figure 27 is the XRPD spectrum of the crystalline form CM-I of Lanifibranor according to the present invention.
  • Fig. 28 is a TGA spectrum of the crystalline form CM-I of Lanifibranor according to the present invention.
  • Figure 29 is the DSC spectrum of the crystalline form CM-I of Lanifibranor according to the present invention.
  • Figure 30 is the 1H NMR spectrum of the crystalline form CM-I of Lanifibranor according to the present invention.
  • These four crystal forms have at least one advantage in terms of solubility, hygroscopicity, mechanical stability, tablet stability, fluidity, process developability, formulation development, purification and powder processing performance. Based on the above findings, the inventors have accomplished the present invention.
  • Libranor raw material refers to various solid forms of the compound of formula Lanifibranor (comprising various crystal forms or amorphous forms mentioned herein, and mentioned in various documents or patents published or unpublished. crystalline or amorphous form).
  • the Lanifibranor raw material used in the present invention is Lanifibranor prepared according to the preparation method provided in the examples of the present invention.
  • a crystalline form of the invention refers to Lanifibranor crystalline forms CM-A, CM-B, CM-C, CM-D, CM-E, CM-F, CM-G and CM-I.
  • the method of "slowly adding” includes but is not limited to: adding drop by drop, adding slowly along the wall of the container.
  • room temperature generally refers to 4-30°C, preferably 20 ⁇ 5°C.
  • a crystalline form of the invention refers to crystalline forms CM-A, CM-B, CM-C, CM-D, CM-E, CM-F, CM-G and CM as described herein -I.
  • the XRPD pattern of crystalline form CM-A includes 4 or more 2 ⁇ values selected from the following group: 9.90° ⁇ 0.2°, 11.70° ⁇ 0.2°, 15.65° ⁇ 0.2°, 17.26° ⁇ 0.2°, 17.96° ⁇ 0.2°, 18.49° ⁇ 0.2°, 20.10° ⁇ 0.2°, 20.57° ⁇ 0.2°, 23.95° ⁇ 0.2°.
  • the XRPD pattern of crystalline form CM-B includes 4 or more 2 ⁇ values selected from the following group: 7.75° ⁇ 0.2°, 8.36° ⁇ 0.2°, 10.89° ⁇ 0.2°, 15.60° ⁇ 0.2°, 16.41° ⁇ 0.2°, 16.77° ⁇ 0.2°, 16.98° ⁇ 0.2°, 17.83° ⁇ 0.2°, 19.14° ⁇ 0.2°, 20.18° ⁇ 0.2°, 22.18° ⁇ 0.2°.
  • the XRPD pattern of the crystalline form CM-F includes 4 or more 2 ⁇ values selected from the following group: 7.76° ⁇ 0.2°, 8.38° ⁇ 0.2°, 10.92° ⁇ 0.2 °, 14.05° ⁇ 0.2°, 15.69° ⁇ 0.2°, 16.48° ⁇ 0.2°, 16.75° ⁇ 0.2°, 17.01° ⁇ 0.2°, 17.87° ⁇ 0.2°, 19.16° ⁇ 0.2°, 20.14° ⁇ 0.2°, 21.11° ⁇ 0.2°, 22.20° ⁇ 0.2°, 24.09° ⁇ 0.2°, 24.40° ⁇ 0.2°, 25.25° ⁇ 0.2°.
  • the XRPD pattern of the crystalline form CM-I includes 4 or more 2 ⁇ values selected from the following group: 7.83° ⁇ 0.2°, 9.70° ⁇ 0.2°, 13.13° ⁇ 0.2 °, 18.43° ⁇ 0.2°, 20.59° ⁇ 0.2°, 23.11° ⁇ 0.2°, 25.32° ⁇ 0.2°.
  • the XRPD pattern of the crystalline form CM-D includes 3 or more 2 ⁇ values selected from the following group: 5.74° ⁇ 0.2°, 9.15° ⁇ 0.2°, 16.39° ⁇ 0.2 °, 20.55° ⁇ 0.2°, 23.67° ⁇ 0.2°.
  • the XRPD pattern of the crystalline form CM-E includes 2 or more 2 ⁇ values selected from the following group: 6.97° ⁇ 0.2°, 11.50° ⁇ 0.2°, 17.33° ⁇ 0.2 °, 18.63° ⁇ 0.2°.
  • the XRPD pattern of the crystalline form CM-G includes 2 or more 2 ⁇ values selected from the following group: 6.09° ⁇ 0.2°, 9.82° ⁇ 0.2°, 17.95° ⁇ 0.2° 0.2°, 18.42° ⁇ 0.2°, 20.96° ⁇ 0.2°, 21.21° ⁇ 0.2°.
  • Another aspect of the present invention provides a pharmaceutical composition, which contains a therapeutically effective amount of Lanifibranor crystal form as described in the present invention, and optionally, one or more pharmaceutically acceptable carriers, excipients, Adjuvants, excipients and/or diluents.
  • the excipients are, for example, flavoring agents, flavoring agents, sweetening agents, and the like.
  • the pharmaceutical composition provided by the present invention preferably contains active ingredients in a weight ratio of 1-99%, and its preferred ratio is that the compound of general formula I accounts for 65wt%-99wt% of the total weight as the active ingredient, and the rest is pharmaceutically acceptable carrier, diluent or solution or saline solution.
  • the compounds and pharmaceutical compositions provided by the present invention can be in various forms, such as tablets, capsules, powders, syrups, solutions, suspensions and aerosols, etc., and can be present in suitable solid or liquid carriers or diluents Neutralize in suitable sterile equipment for injection or infusion.
  • the unit dose of the preparation formula contains 1 mg-700 mg of the compound of general formula I, preferably, the unit dose of the preparation formula contains 25 mg-300 mg of the compound of general formula I.
  • the compounds and pharmaceutical compositions of the present invention can be clinically used in mammals, including humans and animals, and can be administered through oral, nasal, dermal, pulmonary or gastrointestinal routes. Oral administration is most preferred.
  • the most preferred daily dose is 50-1400 mg/kg body weight, taken once, or 25-700 mg/kg body weight in divided doses. Regardless of the method of administration, the optimal dosage for an individual should depend on the specific treatment. Usually, start with a small dose and gradually increase the dose until you find the most suitable dose.
  • the method used for drying is a conventional drying method in the art, for example, drying in the embodiments of the present invention refers to vacuum drying or normal pressure drying in a conventional drying oven. Generally, it is dried for 0.1 to 50 hours or 1 to 30 hours.
  • the main advantages of the present invention include:
  • CM-A, CM-B, CM-F, and CM-I described in the present invention have better thermal stability, pressure stability and chemical stability, and are useful for the preparation and storage of subsequent preparations. important meaning;
  • CM-A, CM-B, CM-F, and CM-I described in the present invention have better fluidity, smaller angle of repose, and low hygroscopicity, which can meet the requirements of direct filling of capsules, and are suitable for Formulation production.
  • test methods of the present invention are general methods, and test parameters are as follows:
  • X-ray powder diffractometer Bruker D2Phaser X-ray powder diffractometer; radiation source Cu Generator (Generator) kv: 30kv; Generator (Generator) mA: 10mA; Initial 2 ⁇ : 2.0°, scanning range: 2.0 ⁇ 35.0°. The scanning speed is 0.1s/step, and the step size is 0.02°/step.
  • X-ray powder diffractometer Bruker D2Phaser X-ray powder diffractometer; radiation source Cu Generator (Generator) kv: 30kv; Generator (Generator) mA: 10mA; Initial 2 ⁇ : 2.0°, scanning range: 2.0 ⁇ 50.0°. The scanning speed is 1s/step, and the step size is 0.02°/step.
  • Thermogravimetric analysis (TGA) instrument TGA55 type of TA Company in the United States, 20-300°C range, heating rate 10°C/min, nitrogen flow rate 40mL/min.
  • DSC Differential scanning calorimetry
  • the obtained Lanifibranor compound crystal form CM-A was tested by XRPD, and the results are shown in FIG. 1 , and the spectrum data are shown in Table 1.
  • the obtained solid was tested by TGA, and the results are shown in Figure 2.
  • the results showed that there was no obvious weight loss step in the TGA spectrum of Lanifibranor crystal form CM-A, and the crystal form was anhydrous; the obtained solid was tested by DSC, and the result As shown in Figure 3, the results show that it has a first endothermic peak at 114.80°C and a second endothermic peak at 179.34°C; the resulting solid was tested by 1H NMR, and the results are shown in Figure 4. Solid microscope observation is block or cuboid.
  • Lanifibranor compound crystal form CM-A At room temperature, add 100 mg of Lanifibranor compound to 8 mL of acetone:ethyl acetate (1:1, v:v) mixed solvent, stir rapidly until dissolved, and then filter through a membrane. The filtrate was placed at room temperature to evaporate the solvent, and a solid was precipitated. After filtering, drying the solid, the obtained solid is Lanifibranor compound crystal form CM-A.
  • the obtained Lanifibranor compound crystal form CM-B was tested by XRPD. The results are shown in FIG. 5 , and the spectral data are shown in Table 2.
  • the TGA test was performed on the obtained solid, and the results are shown in Figure 6.
  • the results show that there is no obvious weight loss peak in the TGA spectrum of Lanifibranor crystal form CM-B in the range of 25°C-150°C, and the crystal form is anhydrous;
  • the obtained solid was tested by DSC, and the results are shown in Figure 7.
  • the results showed that it had a melting endothermic peak at 178.97°C; the obtained solid was tested by 1H NMR, and the results were shown in Figure 8. Solid microscope observation is fine needle.
  • Lanifibranor compound At room temperature, add 100 mg of Lanifibranor compound to 2 mL of 1,4-dioxane, stir rapidly until dissolved, and then filter through a membrane. Put the filtrate in a 20mL glass bottle, add 12mL of ethanol, and place it at 20-25°C to volatilize. Filtrate, volatilize the resulting solid and place it in an oven at 60°C for 12 hours under vacuum to obtain Lanifibranor crystal form CM-C.
  • Lanifibranor compound At room temperature, add 100 mg of Lanifibranor compound to 2 mL of 1,4-dioxane, stir rapidly until dissolved, and then filter through a membrane. Put the filtrate in a 20mL glass bottle, add 12mL of ethanol, and volatilize at 20-25°C. After volatilization for 5 days, a solid is obtained, filtered, and dried in an oven at 25°C for 12h to obtain Lanifibranor crystal form CM-D.
  • the obtained Lanifibranor compound crystal form CM-D was tested by XRPD, the results are shown in Figure 13, and the spectrum data are shown in Table 4; the obtained solid was tested by TGA, and the results were shown in Figure 14, the results showed that Lanifibranor crystal form CM In the TGA spectrum of -D, the weight loss is about 10.08% in the range of room temperature-75°C, about 2.20% in the range of 75°C-115°C, about 5.08% in the range of 115°C-165°C, and about 5.08% in the range of 165°C-210°C About 1.24%, the crystal form is a solvate; DSC test was performed on the obtained solid, and the results are shown in Figure 15. The results showed that each of them had an endothermic peak at 53.27°C, 101.22°C, 122.63°C and 171.01°C.
  • Form CM-D is a solvate.
  • Lanifibranor crystal form CM-E is a solvate of 1,4-dioxane.
  • Embodiment 6 Preparation of Lanifibranor crystal form CM-F
  • Form CM-G is a chloroform solvate.
  • CM-A, CM-B, CM-F and CM-I of the present invention have a higher melting point and better thermal stability than the solid in Example 117 of patent WO2007026097.
  • the crystalline forms CM-A, CM-F and CM-I of the present invention and the crystalline form CM-B can be separated at 25°C/60%RH, 40°C/75%RH and 60°C/92.5%RH Under the conditions, the crystal form stability and chemical stability are good, and the crystal form stability is good under pressure.
  • Form CM-A (Example 1-1), Form CM-B (Example 2-1), Form CM-F (Example 6-1) and Form CM-I (Example 8- 1)
  • Add 100mg each to the buffer solutions of 4 dissolution media (pH1.2, pH4.0, pH6.8 and purified water), stir at 37°C for 2h, detect the solid by XRD, and the test results are shown in Table 4 .
  • the crystalline form CM-B of the present invention is a thermodynamically stable crystalline form at room temperature, and other crystalline forms can be transformed into crystalline form CM-B by induction of the CM-B crystal form in different solvents.
  • crystal form CM-A (Example 1-1), crystal form CM-B (Example 2-1), crystal form CM-F (Example 6-1) and crystal form CM-I (Example 8-1) carried out the hygroscopicity test, and the results are shown in Table 7.
  • the crystalline form CM-A of the present invention has almost no hygroscopicity
  • the crystalline form CM-F and CM-I have slight hygroscopicity
  • the crystalline form CM-B has hygroscopicity.
  • the crystalline form CM-A, crystalline form CM-F and crystalline form CM-I of the present invention have lower hygroscopicity and are convenient for storage and transportation.
  • the preparation includes crystal form CM-A (Example 1-1), crystal form CM-B (Example 2-1), crystal form CM-F (Example 6-1) and crystal form of the present invention
  • CM-I Example 8-1
  • the mixture of CM-I Example 8-1 and the following proportions of excipients was used to detect the angle of repose of the mixture of different crystal forms, and then compare whether the different crystal forms have the feasibility of direct capsule filling.
  • Element Single dose (mg/capsule) APIs 100mg microcrystalline cellulose 150mg lactose 45mg talcum powder 5mg total 300mg
  • the angle of repose of the crystal form CM-A mixture is 31°, and its fluidity fully meets the requirements for direct capsule filling.
  • the angles of repose of the crystal form CM-F mixture and CM-I mixture are 36° and 37°, and their fluidity meets the requirement of direct capsule filling.
  • the crystal form CM-B mixture has an angle of repose of 48°, poor fluidity and cannot meet the requirements of direct capsule filling.
  • the crystalline form CM-A, crystalline form CM-F and CM-I of the present invention have obvious advantages in fluidity after mixing with the auxiliary materials relative to the crystalline form CM-B, and can be directly filled into capsules without preparation preparation.
  • the granule operation simplifies the preparation process and improves the production efficiency of the preparation.
  • tablets can be prepared according to the formulation prescription in Table 10 below.
  • Element Single dose (mg/capsule) APIs 100mg microcrystalline cellulose 135mg lactose 45mg hypromellose 15mg talcum powder 5mg total 250mg
  • Preparation method mix Lanifibranor with microcrystalline cellulose and lactose, pass through an 80-mesh sieve and mix, then add hypromellose aqueous solution to make a soft material, pass through a 20-mesh sieve to granulate, dry, add talcum powder, mix evenly, and press into tablets.

Abstract

La présente invention concerne une forme cristalline de lanifibranor, et son procédé de préparation. Plus particulièrement, la présente invention concerne une forme cristalline d'un composé représenté par la formule 1. La forme cristalline est la forme cristalline CM-A, la forme cristalline CM-B, la forme cristalline CM-C, la forme cristalline CM-D, la forme cristalline CM-E, la forme cristalline CM-F, la forme cristalline CM-G ou la forme cristalline CM-I. Par rapport au lanifibranor solide, la forme cristalline de lanifibranor selon la présente invention a une stabilité supérieure, une hygroscopicité inférieure et une meilleure fluidité, et offre un meilleur choix pour le développement d'un médicament contenant du lanifibranor.
PCT/CN2022/098241 2021-06-11 2022-06-10 Forme cristalline de lanifibranor et son procédé de préparation WO2022258060A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280036190.5A CN117545755A (zh) 2021-06-11 2022-06-10 一种Lanifibranor的晶型及其制备方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110655795.XA CN115466252A (zh) 2021-06-11 2021-06-11 一种Lanifibranor的晶型及其制备方法
CN202110655795.X 2021-06-11

Publications (1)

Publication Number Publication Date
WO2022258060A1 true WO2022258060A1 (fr) 2022-12-15

Family

ID=84364721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/098241 WO2022258060A1 (fr) 2021-06-11 2022-06-10 Forme cristalline de lanifibranor et son procédé de préparation

Country Status (2)

Country Link
CN (2) CN115466252A (fr)
WO (1) WO2022258060A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023194339A1 (fr) 2022-04-05 2023-10-12 Inventiva Forme cristalline de lanifibranor

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248044A (zh) * 2005-08-30 2008-08-20 实验室富尼耶公司 新的吲哚化合物
CN109316601A (zh) * 2017-07-31 2019-02-12 武汉朗来科技发展有限公司 药物组合物及其用途
IN201911052572A (fr) * 2019-12-18 2021-09-03 Mankind Pharma Ltd.
CN114478512A (zh) * 2020-10-27 2022-05-13 广东东阳光药业有限公司 一种酸的晶型及其制备方法
CN114621211A (zh) * 2020-12-11 2022-06-14 苏州科睿思制药有限公司 Lanifibranor的晶型及其制备方法和用途
CN114621212A (zh) * 2020-12-11 2022-06-14 苏州科睿思制药有限公司 Lanifibranor的晶型及其制备方法和用途
WO2022122014A1 (fr) * 2020-12-11 2022-06-16 苏州科睿思制药有限公司 Forme cristalline du lanifibranor, son procédé de préparation et son utilisation
WO2022143479A1 (fr) * 2020-12-29 2022-07-07 广东东阳光药业有限公司 Forme solide de composé, son procédé de préparation et son utilisation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248044A (zh) * 2005-08-30 2008-08-20 实验室富尼耶公司 新的吲哚化合物
CN109316601A (zh) * 2017-07-31 2019-02-12 武汉朗来科技发展有限公司 药物组合物及其用途
IN201911052572A (fr) * 2019-12-18 2021-09-03 Mankind Pharma Ltd.
CN114478512A (zh) * 2020-10-27 2022-05-13 广东东阳光药业有限公司 一种酸的晶型及其制备方法
CN114621211A (zh) * 2020-12-11 2022-06-14 苏州科睿思制药有限公司 Lanifibranor的晶型及其制备方法和用途
CN114621212A (zh) * 2020-12-11 2022-06-14 苏州科睿思制药有限公司 Lanifibranor的晶型及其制备方法和用途
WO2022122014A1 (fr) * 2020-12-11 2022-06-16 苏州科睿思制药有限公司 Forme cristalline du lanifibranor, son procédé de préparation et son utilisation
WO2022143479A1 (fr) * 2020-12-29 2022-07-07 广东东阳光药业有限公司 Forme solide de composé, son procédé de préparation et son utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BENAÏSSA BOUBIA; OLIVIA POUPARDIN; MARTINE BARTH; JEAN BINET; PHILIPPE PERALBA; LAURENT MOUNIER; ELISE JACQUIER; EMILIE GAUTHIER; : "Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) alpha/gamma/delta Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate", JOURNAL OF MEDICAL CHEMISTRY, vol. 61, no. 6, 22 March 2018 (2018-03-22), pages 2246 - 2265, XP002790345, DOI: 10.1021/acs.jmedchem.7b01285 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023194339A1 (fr) 2022-04-05 2023-10-12 Inventiva Forme cristalline de lanifibranor

Also Published As

Publication number Publication date
CN115466252A (zh) 2022-12-13
CN117545755A (zh) 2024-02-09

Similar Documents

Publication Publication Date Title
CN108026075B (zh) 普那布林组合物
WO2017215617A1 (fr) Forme cristalline de l'ozanimod, forme cristalline de son hydrochloride et son procédé de préparation
WO2018184185A1 (fr) Cristal de sel d'addition d'ozanimod, procédé de préparation, composition pharmaceutique, et utilisations
US11286259B2 (en) Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof
BR112019021447A2 (pt) sal fumarato, forma cristalina i do referido sal, métodos para preparação dos mesmos, composição farmacêutica compreendendo o sal e a forma cristalina i e uso do sal fumarato, da forma cristalina i e da composição farmacêutica
AU2019238090A1 (en) Crystalline forms and methods of producing crystalline forms of a compound
WO2016155670A1 (fr) Inhibiteur de cdk, cristal eutectique d'inhibiteur de mek, et leur procédé de préparation
WO2022258060A1 (fr) Forme cristalline de lanifibranor et son procédé de préparation
WO2018103726A1 (fr) Forme cristalline d'un médicament inhibiteur de protéine de bromodomaine, son procédé de préparation et son utilisation
JP2018516946A (ja) ヒストン脱アセチル化阻害剤の結晶形態
WO2019183916A1 (fr) Cristal eutectique de fruquintinib, son procédé de préparation, sa composition et ses applications
WO2018133705A1 (fr) Forme cristalline de gft-505 et procédé de préparation et d'utilisation de celle-ci
WO2023193563A1 (fr) Forme cristalline d'un composé thiénopyridine, son procédé de préparation et composition pharmaceutique associée
WO2019205812A1 (fr) Nouvelle forme cristalline de l'acalabrutinib, son procédé de préparation et son utilisation
JP7275253B2 (ja) Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
WO2018103027A1 (fr) Forme cristalline de tipifarnib, procédé de préparation et composition pharmaceutique associés
TWI378929B (en) Crystalline 1h-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
WO2021000687A1 (fr) Procédé de préparation d'une forme cristalline de pac-1
US9598413B2 (en) Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
WO2018137670A1 (fr) Forme cristalline du médicament inhibiteur de protéine virale (vx-287), et son procédé de préparation et d'utilisation
WO2022194160A1 (fr) Forme solide de fisogatinib et son procédé de préparation
EP3412661A1 (fr) Co-cristaux de bromhydrate vortioxetine et du résorcinol
WO2018001335A1 (fr) Formes cristallines de nbi-98854, procédé de préparation s'y rapportant et utilisation associée
US20220389022A1 (en) Solid forms of ponatinib hydrochloride and process thereof
WO2017076358A1 (fr) Nouvelle forme cristalline de sel de composé imidazolyl-biphényl et son procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22819656

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE